UBS considers the impact of the Kisqali production adjustments to be limited. The analyst confirms his Buy recommendation on the stock, with a price target of E104, representing a 20% upside potential.

' The manufacturing adjustments should be implemented by the end of the second quarter, and the regulatory review of Natalee should proceed as planned' says UBS.

It should be recalled that the Group has revised its medium-term forecasts, now expecting net sales to rise by an average annual CCT of 5% over 2023-28, and a core operating profit margin growing by around 40% or more by 2027.

Copyright (c) 2024 All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.